Healthcare / BiotechnologyNasdaqGS
$1.84
-0.03 (-1.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-241.1M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$490M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-161.4%
↓Gross Margin
-27.8%
↓Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-412.1%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $75.4M · net income $-287.5M · FCF $-310.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $75.4M | $75.4M | $10.1M | $1.7M | $6.2M | — |
| Net Income | $-287.5M | $-287.5M | $-220.7M | $-208.4M | $-148.8M | $-142.1M |
| EBITDA | $-239.1M | $-239.1M | $-202.1M | $-156.8M | $-132.2M | $-132.6M |
| EPS | -1.08 | -1.08 | -0.86 | -1.20 | -1.57 | -1.97 |
| Gross Margin | -27.8% | -27.8% | -12.5% | 100.0% | — | — |
| Operating Margin | -358.9% | -358.9% | -2385.6% | -10337.3% | -2307.0% | — |
| Net Margin | -381.4% | -381.4% | -2180.5% | -12272.3% | -2403.0% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.40 | 0.40 | 0.12 | 0.48 | 0.08 | — |
| Current Ratio | 11.05 | 11.05 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-310.7M | $-310.7M | $-241.1M | $-156.6M | $-123.1M | $-126.7M |
| Returns | ||||||
| ROE | -161.4% | -161.4% | -51.6% | -186.9% | -49.8% | -45.4% |
| Valuation | ||||||
| P/B | 2.75 | 2.75 | 1.60 | 9.80 | 0.57 | — |
| Growth & Yield | ||||||
| Revenue Growth | 644.9% | 644.9% | 496.0% | -72.6% | — | — |
| EPS Growth | -25.6% | -25.6% | 28.3% | 23.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.86 → -1.08
Residual
+5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.